According to the research report titled, 'Transcriptomics Market by Product & Services (Consumables, Instruments, Software & Services), Technology (Next-Generation Sequencing, PCR-based Technologies), Application (Drug Discovery & Development, Clinical Diagnostic), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), and Geography - Global Forecast to 2035,' the transcriptomics market is projected to reach $15.32 billion by 2035, at a CAGR of 6.3% during the forecast period 2025-2035. The report provides an in-depth analysis of the global transcriptomics market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2035.
Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by rapid advancements in next-generation sequencing (NGS) technologies, growing demand for personalized medicine, increasing prevalence of cancer and chronic diseases, expanding applications in drug discovery and development, and declining sequencing costs. Moreover, integration of single-cell and spatial transcriptomics workflows, rise of multi-omics approaches, implementation of artificial intelligence and machine learning in data analysis, expansion of clinical transcriptomics for diagnostics, and growing government funding for genomics research are expected to support the market's growth.
The key players operating in the transcriptomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), 10x Genomics, Inc. (U.S.), Takara Bio Inc. (Japan), Oxford Nanopore Technologies Ltd. (U.K.), Pacific Biosciences of California, Inc. (U.S.), Merck KGaA (Germany), Bruker Corporation (U.S.), PerkinElmer, Inc. (U.S.), Fluidigm Corporation (U.S.), and Promega Corporation (U.S.).
The transcriptomics market is segmented by product & services (consumables, instruments, and software & services), technology (next-generation sequencing, microarrays, PCR-based technologies, and other technologies), application (drug discovery & development, clinical diagnostics, personalized medicine, agricultural & animal research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, clinical diagnostic laboratories, contract research organizations, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.
However, the consumables segment is also expected to register the highest CAGR of 7.2% during the forecast period, driven by rising adoption of NGS-based RNA-seq and single-cell transcriptomics, expansion of sequencing service providers and decentralized testing, increasing throughput requirements across research and clinical settings, and development of innovative reagent formulations for emerging applications.
The next-generation sequencing segment is also projected to register the highest CAGR of 7.3% during the forecast period, attributed to ongoing technological innovations improving sequencing accuracy and throughput, expanding applications in precision medicine and clinical diagnostics, increasing investments in genomics infrastructure by pharmaceutical and biotechnology companies, development of long-read sequencing technologies for comprehensive transcript characterization, and growing preference for comprehensive molecular profiling in research and clinical settings.
However, the personalized medicine segment is projected to register the highest CAGR of 8.0% during the forecast period, driven by increasing need for precise, patient-specific insights beyond traditional genetic testing, real-time measurement of gene expression for understanding disease pathways and drug response, rapid adoption of RNA-based biomarkers in oncology, immunology, and rare diseases, integration of precision medicine programs in healthcare systems, and growing requirement for transcriptomic profiling in guiding targeted therapies and monitoring therapeutic efficacy.
Along with pharmaceutical & biotechnology companies, the contract research organizations (CROs) segment is also expected to register the highest CAGR of 7.1% during the forecast period. This rapid growth is driven by increasing outsourcing of RNA-seq, single-cell sequencing, and spatial transcriptomics services, complexity and high cost of advanced transcriptomic workflows making outsourcing attractive, CROs offering end-to-end solutions from sample preparation to bioinformatics interpretation, growing demand for specialized expertise and scalable infrastructure, and expansion of service portfolios to include cutting-edge technologies and AI-powered analytics.
North America is expected to account for the largest share of approximately 40% of the global transcriptomics market in 2025. This dominance is attributed to strong presence of leading biotechnology and pharmaceutical companies, well-established genomics research infrastructure, high adoption of advanced sequencing technologies, substantial government and private funding for genomics research through the National Institutes of Health and other organizations, and early adoption of transcriptomic diagnostics in clinical practice. The region benefits from comprehensive healthcare systems, major research institutions, and significant investments in precision medicine initiatives.
However, Asia-Pacific is projected to register the highest CAGR during the forecast period across the overall transcriptomics market. This growth is fueled by increasing investments in genomics research infrastructure, growing pharmaceutical and biotechnology sectors in countries like China and India, rising healthcare expenditure and improving access to advanced diagnostics, expanding academic research collaborations with Western institutions, government initiatives supporting precision medicine and genomics programs, and large-scale population genomics projects. Countries such as China have made substantial investments in genomics capabilities and launched national genomics programs. The region's growing middle-class population, improving healthcare infrastructure, increasing focus on personalized medicine, and supportive regulatory frameworks for genomics research are creating a conducive environment for market expansion. Additionally, the region's expanding clinical research activities, growing contract research organizations, and increasing pharmaceutical R&D investments contribute to higher adoption of transcriptomic technologies.
Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by rapid advancements in next-generation sequencing (NGS) technologies, growing demand for personalized medicine, increasing prevalence of cancer and chronic diseases, expanding applications in drug discovery and development, and declining sequencing costs. Moreover, integration of single-cell and spatial transcriptomics workflows, rise of multi-omics approaches, implementation of artificial intelligence and machine learning in data analysis, expansion of clinical transcriptomics for diagnostics, and growing government funding for genomics research are expected to support the market's growth.
The key players operating in the transcriptomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), 10x Genomics, Inc. (U.S.), Takara Bio Inc. (Japan), Oxford Nanopore Technologies Ltd. (U.K.), Pacific Biosciences of California, Inc. (U.S.), Merck KGaA (Germany), Bruker Corporation (U.S.), PerkinElmer, Inc. (U.S.), Fluidigm Corporation (U.S.), and Promega Corporation (U.S.).
The transcriptomics market is segmented by product & services (consumables, instruments, and software & services), technology (next-generation sequencing, microarrays, PCR-based technologies, and other technologies), application (drug discovery & development, clinical diagnostics, personalized medicine, agricultural & animal research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, clinical diagnostic laboratories, contract research organizations, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.
Market Analysis by Segments
Based on Product & Services
The consumables segment is projected to account for the largest market share of approximately 51% in 2025. The dominance of this segment is primarily attributed to the recurring and high-volume nature of consumable usage across RNA-based workflows, continuous consumption of reagents for every sample processed, advancements in library preparation chemistries and automation-compatible reagent kits, and growing adoption of specialized consumables for low-input and single-cell samples. Transcriptomic studies require ongoing consumption of RNA extraction kits, library preparation kits, sequencing reagents, and PCR consumables, making this a key revenue driver for vendors.However, the consumables segment is also expected to register the highest CAGR of 7.2% during the forecast period, driven by rising adoption of NGS-based RNA-seq and single-cell transcriptomics, expansion of sequencing service providers and decentralized testing, increasing throughput requirements across research and clinical settings, and development of innovative reagent formulations for emerging applications.
Based on Technology
The next-generation sequencing segment is expected to dominate the transcriptomics market in 2025, accounting for approximately 71% market share. This segment's leadership is primarily driven by comprehensive transcriptome coverage provided by NGS technologies, continuous decline in sequencing costs making NGS accessible to more laboratories, superior ability to detect novel transcripts and splice variants compared to other technologies, growing adoption of single-cell and spatial transcriptomics applications exclusively enabled by sequencing approaches, and preference for hypothesis-free discovery approaches. NGS enables unbiased transcriptome-wide analysis, providing insights into gene expression, alternative splicing, and transcript isoforms that are not possible with targeted methods.The next-generation sequencing segment is also projected to register the highest CAGR of 7.3% during the forecast period, attributed to ongoing technological innovations improving sequencing accuracy and throughput, expanding applications in precision medicine and clinical diagnostics, increasing investments in genomics infrastructure by pharmaceutical and biotechnology companies, development of long-read sequencing technologies for comprehensive transcript characterization, and growing preference for comprehensive molecular profiling in research and clinical settings.
Based on Application
The drug discovery & development segment is expected to account for the largest share of approximately 35% of the transcriptomics market in 2025. This leadership is attributed to extensive use of transcriptomics throughout pharmaceutical development pipelines, growing investments in biologics and precision medicine requiring molecular characterization, increasing adoption of target-based drug discovery approaches, expanding applications in biomarker discovery for patient stratification, and utility in understanding mechanism of action and safety profiling. Pharmaceutical companies leverage transcriptomics to identify therapeutic targets, evaluate drug efficacy, understand treatment resistance mechanisms, and guide clinical trial design.However, the personalized medicine segment is projected to register the highest CAGR of 8.0% during the forecast period, driven by increasing need for precise, patient-specific insights beyond traditional genetic testing, real-time measurement of gene expression for understanding disease pathways and drug response, rapid adoption of RNA-based biomarkers in oncology, immunology, and rare diseases, integration of precision medicine programs in healthcare systems, and growing requirement for transcriptomic profiling in guiding targeted therapies and monitoring therapeutic efficacy.
Based on End User
The pharmaceutical & biotechnology companies segment is expected to account for the largest share of approximately 40% of the transcriptomics market in 2025. This dominance is primarily driven by extensive use of transcriptomics throughout drug discovery and development pipelines, growing investments in precision medicine initiatives requiring molecular profiling, increasing adoption of transcriptomics in clinical trials for patient stratification, ongoing development of RNA-based therapeutics necessitating comprehensive transcriptomic characterization, and establishment of in-house sequencing capabilities for high-throughput analysis. These companies utilize transcriptomics for target identification, lead optimization, biomarker discovery, and companion diagnostics development.Along with pharmaceutical & biotechnology companies, the contract research organizations (CROs) segment is also expected to register the highest CAGR of 7.1% during the forecast period. This rapid growth is driven by increasing outsourcing of RNA-seq, single-cell sequencing, and spatial transcriptomics services, complexity and high cost of advanced transcriptomic workflows making outsourcing attractive, CROs offering end-to-end solutions from sample preparation to bioinformatics interpretation, growing demand for specialized expertise and scalable infrastructure, and expansion of service portfolios to include cutting-edge technologies and AI-powered analytics.
Geographic Analysis
An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region.North America is expected to account for the largest share of approximately 40% of the global transcriptomics market in 2025. This dominance is attributed to strong presence of leading biotechnology and pharmaceutical companies, well-established genomics research infrastructure, high adoption of advanced sequencing technologies, substantial government and private funding for genomics research through the National Institutes of Health and other organizations, and early adoption of transcriptomic diagnostics in clinical practice. The region benefits from comprehensive healthcare systems, major research institutions, and significant investments in precision medicine initiatives.
However, Asia-Pacific is projected to register the highest CAGR during the forecast period across the overall transcriptomics market. This growth is fueled by increasing investments in genomics research infrastructure, growing pharmaceutical and biotechnology sectors in countries like China and India, rising healthcare expenditure and improving access to advanced diagnostics, expanding academic research collaborations with Western institutions, government initiatives supporting precision medicine and genomics programs, and large-scale population genomics projects. Countries such as China have made substantial investments in genomics capabilities and launched national genomics programs. The region's growing middle-class population, improving healthcare infrastructure, increasing focus on personalized medicine, and supportive regulatory frameworks for genomics research are creating a conducive environment for market expansion. Additionally, the region's expanding clinical research activities, growing contract research organizations, and increasing pharmaceutical R&D investments contribute to higher adoption of transcriptomic technologies.
Key Questions Answered in the Report
- What is the current revenue generated by the transcriptomics market globally?
- At what rate is the global transcriptomics demand projected to grow for the next 7-10 years?
- What are the historical market sizes and growth rates of the global transcriptomics market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of product & services, technology, application, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global transcriptomics market?
- Who are the major players in the global transcriptomics market? What are their specific product offerings in this market?
- What are the recent strategic developments in the global transcriptomics market? What are the impacts of these strategic developments on the market?
Scope of the Report
Transcriptomics Market Assessment - by Product & Services
- Consumables
- Instruments
- Software & Services
Transcriptomics Market Assessment - by Technology
- Next-Generation Sequencing (NGS)
- Microarrays
- PCR-based Technologies
- Other Technologies
Transcriptomics Market Assessment - by Application
- Drug Discovery & Development
- Clinical Diagnostics
- Personalized Medicine
- Agricultural & Animal Research
- Other Applications
Transcriptomics Market Assessment - by End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Diagnostic Laboratories
- Contract Research Organizations (CROs)
- Other End Users
Transcriptomics Market Assessment - by Geography
North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia & New Zealand
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
Table of Contents
1 Introduction
2 Research Methodology
4 Market Insights
5 Global Transcriptomics Market Assessment - By Product & Service
6 Global Transcriptomics Market Assessment - By Technology
7 Global Transcriptomics Market Assessment - By Application
8 Global Transcriptomics Market Assessment - By End User
9 Transcriptomics Market Assessment, By Geography
10 Competitive Landscape
11 Company Profiles
12 Appendix
Companies Mentioned
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories Inc.
- F. Hoffmann-La Roche Ltd
- 10x Genomics Inc.
- Takara Bio Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
- Merck KGaA
- Bruker Corporation
- PerkinElmer Inc.
- Fluidigm Corporation
- Promega Corporation.
